Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.

Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.

Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I.

Pediatr Infect Dis J. 2008 Dec;27(12):1052-6. doi: 10.1097/INF.0b013e3181861dd7.

PMID:
18978514
2.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
3.

Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.

Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.

Vaccine. 2010 Aug 31;28(38):6221-7. doi: 10.1016/j.vaccine.2010.07.008. Epub 2010 Jul 16.

PMID:
20638454
5.

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.

Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.

Pediatr Infect Dis J. 2010 Jun;29(6):e35-46. doi: 10.1097/INF.0b013e3181daf921.

PMID:
20375709
6.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
7.

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F.

Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20.

PMID:
22192847
8.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.

PMID:
19835829
9.

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.

Vaccine. 2009 Dec 30;27 Suppl 6:G60-6. doi: 10.1016/j.vaccine.2009.10.031.

PMID:
20006142
10.

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M.

N Engl J Med. 2006 Mar 30;354(13):1343-51.

11.

Influenza A (H5N1) pandemic prototype vaccine Fluval.

Vajo Z.

Expert Rev Vaccines. 2009 May;8(5):619-24. doi: 10.1586/erv.09.25. Review.

PMID:
19397418
12.

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.

PMID:
21606530
13.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.

J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916.

PMID:
18694338
14.

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L.

J Infect Dis. 2010 Jun 1;201(11):1644-53. doi: 10.1086/652701.

PMID:
20423222
15.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.

J Infect Dis. 2008 Sep 1;198(5):642-9. doi: 10.1086/590913.

PMID:
18576945
16.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
17.

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6.

PMID:
20819892
18.

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.

Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.

Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12.

PMID:
22080174
20.

[Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].

Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Jul;24(7):570-3. Chinese.

PMID:
12975010

Supplemental Content

Support Center